Product Description
Mechanisms of Action: CAR-T,NK
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Simnova Biotechnology
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for SNC-115](https://pryzm-maps.s3.us-west-2.amazonaws.com/12current_maps.png)
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Large Cell Carcinoma|Neuroendocrine Carcinoma|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
SNC115-DLL3 CART-101 | P1 |
Recruiting |
Large Cell Carcinoma|Small Cell Lung Cancer|Neuroendocrine Carcinoma |
2025-04-30 |
44% |